KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted) (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.17 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 70.18% year-over-year to -$0.17, compared with a TTM value of -$1.44 through Dec 2025, up 15.29%, and an annual FY2025 reading of -$1.44, up 14.79% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.17 for Q4 2025 at Recursion Pharmaceuticals, up from -$0.36 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.17 in Q4 2025 and bottomed at -$1.33 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.42, with a median of -$0.38 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 56.47% in 2021, then surged 75.19% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.39 in 2021, then rose by 23.08% to -$0.3 in 2022, then crashed by 40.0% to -$0.42 in 2023, then plummeted by 35.71% to -$0.57 in 2024, then soared by 70.18% to -$0.17 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RXRX at -$0.17 in Q4 2025, -$0.36 in Q3 2025, and -$0.41 in Q2 2025.